New imaging agent aims to unmask hidden prostate cancer recurrences

NCT ID NCT06813898

Recruiting now Diagnosis Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial tests whether a special PET/CT scan using a tracer called POSLUMA can detect prostate cancer in men whose PSA levels are rising after treatment but who had negative results on standard PET scans. The study enrolls men with biochemical recurrence and low PSA levels. Researchers will compare the scan findings to tissue samples or follow-up imaging to see how often POSLUMA spots cancer that other scans missed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F-18 Gallium (POSLUMA)
What this could lead to: If successful, this imaging method could help doctors find hidden prostate cancer recurrences earlier, guiding more precise treatment.
What could go wrong: This is an early-phase trial with only 27 participants, so results may not apply broadly. The scan might still miss some cancers or find false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOCHEMICALLY RECURRENT PROSTATE CARCINOMA PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.